When a patient presents with end stage liver disease or liver failure he or she may be considered for a liver transplantation. The first step in this is often a rigorous assessment and being placed on a waiting list.
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide. NAFLD patients are at higher risk of developing Non-alcoholic steatohepatitis (NASH), which causes severe and chronic liver inflammation, fibrosis and liver damage.
Researchers from the Faculty of Medicine of the University of Barcelona and the CELLEX Biomedical Research Centre from IDIBAPS have identified in a study with mice a protein which is fundamental to guarantee the restoration and regeneration of the liver after a transplant or hepatic surgery.